Key result
Dabigatran use in elderly patients with nonvalvular atrial fibrillation has a similar or lower risk of bleeding compared with warfarin therapy, suggesting advanced age alone should not exclude its use.
Why the study?
Does dabigatran safely prevent stroke in elderly patients with nonvalvular atrial fibrillation compared to warfarin?
Population
Elderly patients (≥75 years of age) with nonvalvular atrial fibrillation
Comparison
Dabigatran (dabigatran etexilate) vs Warfarin therapy
Design
Review
Authors
Loading...
Should not yet change practice in elderly nonvalvular AF; leaves open need for RCTs to confirm bleeding safety.
Does dabigatran safely prevent stroke in elderly patients with nonvalvular atrial fibrillation compared to warfarin?
Advanced age alone should not exclude the use of dabigatran for stroke prevention in nonvalvular atrial fibrillation, as observational data suggest bleeding risks are comparable to or lower than warfarin.
Brunetti et al. (2014) conducted a review in Nonvalvular atrial fibrillation. Dabigatran vs. Warfarin was evaluated on Stroke prevention and bleeding complications. Dabigatran use in elderly patients with nonvalvular atrial fibrillation has a similar or lower risk of bleeding compared with warfarin therapy, suggesting advanced age alone should not exclude its use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: